Navigation Links
Sale of Enzymatic Therapy, Inc. to Nature's Way Holding Company Finalized
Date:11/10/2008

's Way, will be the Chief Operating Officer. Both Mr. Rose and Mr. Mahony will join the Board of Directors for the new corporate entity.

Nature's Way Holding Company operates manufacturing and distribution facilities in Utah and Wisconsin, and has offices across the United States, including those in New York City, St Louis, Missouri, Green Bay, Wisconsin, and in Springville, Utah. It also has a marketing and distribution company in Canada.

Consumer enthusiasm for the Enzymatic and Nature's Way products has resulted in strong and steady growth of the brands. Going forward, the company will focus on further acceleration of these very positive growth rates by continuing to deliver quality products that meet customer needs.


'/>"/>
SOURCE Nature's Way Holding Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. What Boomers Need to Know About Digestion; Enzymatic Therapy's CompleteGest1 Renew targets special digestive issues
2. Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Natures Way Holding, Inc.
3. Dr. Ajrawats Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark
4. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
5. Skin flaps deliver cancer-fighting therapy, ASPS study reveals
6. American Humane Forms Human-Animal Bond Division, Including Animal-Assisted Therapy, Humane Ed and Pets & Womens Shelters
7. Smoking Cessation Rates Double With Intensive Counseling and Free Nicotine Replacement Therapy, Studies of 20,000 Smokers Show
8. To evade chemotherapy, some cancer cells mimic stem cells
9. ProGenTech Targets Clinical Diagnostics and Applied Sciences Markets with Human Genetic Signatures Deal
10. Statement Regarding the Filing of Signatures to Put the Human Embryo Stem Cell Issue on the November Statewide Ballot
11. As I-1000 Signatures are Counted, Washington State Medical Association Opposition to Physician-Assisted Suicide Reiterated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Surgeons at the Forbes Hospital ... Network, are exploring an innovative use of Google ... Zonal Reminder (VIZR), to assist in the care of ... is a wearable technology with an optical head-mounted display ... communicate with the Internet via natural language voice commands. ...
(Date:3/2/2015)... March 02, 2015 Ticket Down is ... the Hollywood Bowl . This popular site has reduced ... promo code JIMMY-BUFFETT-2015 for added savings. , Parrotheads in ... performer will be headlining at the Hollywood Bowl for ... be on Thursday, October 22nd and it will be ...
(Date:3/2/2015)... Doctors in Novara, Italy have found that ... outcomes for people with mesothelioma than other clinical factors. ... new study on the Surviving Mesothelioma website. , ... Piedmont followed the cases of 172 mesothelioma patients ... fluid. , “Persistent lung expansion after pleural talc ...
(Date:3/2/2015)... 2015 Burns Engineering's Lab-to-Lab Calibration ... Secondary Standard Platinum Resistance Thermometers (SSPRTs) and industrial ... or less . . . guaranteed. ... (Lab Code 200706-0), ISO 9001 and 17025 Certified ... is -196°C to 500°C, both ITS-90 and Callendar-van ...
(Date:3/2/2015)... The minimally invasive surgical instruments market is ... to reach $14,133.0 million by 2019 from $10,526.2 ... advantages of minimally invasive surgeries over traditional open ... surgeries and increasing number of surgical procedures among ... invasive surgical instruments market. , For More Details ...
Breaking Medicine News(10 mins):Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:Cheap Jimmy Buffett Tickets Hollywood Bowl: Ticket Down Slashes Prices on Jimmy Buffett Tickets at the Hollywood Bowl in Los Angeles/Hollywood, CA 2Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2
... In a decision of broad impact to medical malpractice ... refused to apply the state,s "cap" on non-economic damages ... when the Maryland General Assembly revised the damage cap ... could recover from negligent doctors and hospitals, the legislature ...
... April 21 Hudson Institute is pleased to welcome ... of Health and Human Services (HHS) under George W. ... Troy will write on health care, medical innovation, and ... around the corner, we are very fortunate to have ...
... Cancer Research,s 100th Annual Meeting 2009 -SOUTH SAN FRANCISCO, ... (Nasdaq: PARD ), a biopharmaceutical company focused ... from a Phase 1 clinical study of an oral ... showed that the bioavailability of oral picoplatin is nearly ...
... device for the treatment of depression named one ... 21 - NeuroStar(R) TMS (Transcranial Magnetic Stimulation) Therapy ... treatment cleared by the FDA for Major Depressive ... Design Excellence Award (MDEA). The award will be ...
... 21 Frost & Sullivan presented ... Pacific,s Healthcare sector at the 2009 Frost ... Awards held today at the InterContinental hotel in ... consecutive year, the awards banquet recognised companies across ...
... HRC ) fiscal 2009 second quarter earnings release will ... participate in a webcast the following morning on May 5, 2009 ... Holdings, Inc.,s Fiscal 2009 Second Quarter Release for the quarter ended ... NYSE close on Monday, May 4, 2009. The release will ...
Cached Medicine News:Health News:Judge Holds Maryland Damages Cap Not Applicable to Malpractice Cases 2Health News:Judge Holds Maryland Damages Cap Not Applicable to Malpractice Cases 3Health News:Former HHS Deputy Secretary Tevi Troy Joins Hudson Institute 2Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 2Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 3Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 4Health News:Photos: NeuroStar TMS Therapy(R) Recipient of Medical Design Excellence Award 2Health News:Photos: NeuroStar TMS Therapy(R) Recipient of Medical Design Excellence Award 3Health News:Outstanding Healthcare Companies in Asia Pacific Honored 2Health News:Outstanding Healthcare Companies in Asia Pacific Honored 3Health News:Outstanding Healthcare Companies in Asia Pacific Honored 4Health News:Outstanding Healthcare Companies in Asia Pacific Honored 5Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Second Quarter Earnings Webcast 2
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ... the successful completion of a Phase 1 clinical ... DUR-928 is an endogenous, small-molecule, new chemical entity ... diseases such as nonalcoholic fatty liver disease (NAFLD) ... injuries such as acute kidney injury (AKI).        ...
(Date:3/2/2015)... 2, 2015  Intrexon Corporation (NYSE: ... announced its fourth quarter and full year results ... Recent Developments: , Acquired ActoGeniX, a European ... in cellular therapeutics and other innovative products.  Its ... food-grade microbes ( Lactococcus lactis ) to generate ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... Centra-GP6R general purpose centrifuges offer high-volume versatility ... rotor options, making them ideal for a ... Versatility , Four- or six-place sealed ... oil tube rotors offered , Lare capacity ...
... Centrifuges feature powerful, maintenance-free motors, ... of rotors for unparalleled application ... in one: a high capacity ... harvesting; a high-speed centrifuge for ...
... MicroCentrifuge Two Strip Rotor hold 16 0.2ml ... with). Simply close the polycarbonate lid to ... open. Starts and stops in seconds. Maximum ... g. Only five inches in diameter. Also ...
Medicine Products: